The efficacy of commercially-prepared IV infusions of pooled human immunoglohulin G (IVIG) was evaluated in the treatment of Pneumocystis carinii pneumonia (PCP) in the immunosuppressed rat model
Sattler F R, Cowan R, Nielsen D M, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988; 109:280–287.
A recent clinical trial in patients with AID S~7 has demonstrated the prophylactic efficacy of a weekly oral dose of Ioo, 20o or 3oo mg dapsone. References I. Kovacs JA, Masur H. Pneumocystis carinii pneumonia: therapy and prophylaxis. J Infect Dis I988; I58: 254-259. 2. Ivady G, Paldy L, Koltay M, Toth G, Kovacs Z. Pneumocystis carinii pneumonia.
Clarkson AB, Jr, Sarić M, Grady RW. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep; 34 (9):1833–1835. [PMC free article] Davey RT, Jr, Masur H. Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia.
Antimicrobial drugs that can be taken orally are needed for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). the rat model of
Treatment and Prophylaxis for Pneumocystis carinii Pneumonia W. T, Hughes Without treatment, Pneumocystis carinii pneumonitis is almost always fatal in the immuno- compromised host. Here, Walter Hughes discusses proven and potential treatments, and methods of …
Immunization with Pneumocystis carinii gpA Is Immunogenic but Not Protective in a Mouse Model of P. carinii Pneumonia Francis Gigliotti , 1, * James A. Wiley , 2 and Allen G. Harmsen 2 University of Rochester School of Medicine, Rochester, New York 14642, 1 and The Trudeau Institute, Saranac Lake, New York 12983 2
Similar effects of intravenous immune globulin prophylaxis are seen in chronic lymphocytic leukemia, in which the treatment predominantly reduces the incidence of clinically diagnosed pneumonia
In conclusion, a rat model of triple infection with P. carinii, T. gondii, and M. aviumhas been designed and has been used to demonstrate the efficacies of several drug combinations. Compared to separate models of single infections, which often use different animal species, this model offers the opportunity to evaluate simultaneously the activities of drugs against different pathogens.
Published in: Antimicrobial Agents and Chemotherapy · 1998Authors: Monique Brunpascaud · Premavathy Rajagopalanlevasseur · Francoise Chau · Guylen…About: Apicomplexa · Bacteria · Immunosuppression · Protozoa · Drug interaction · Opportuni…
An Improved Rat Model to Study Efficacy of Drugs for Treatment or Prophylaxis of Pneumocystis carinii Pneumonia Article in The Journal of protozoology 36(1):77S-78S · January 2007 with 3 Reads
An improved rat model to study efficacy of drugs for treatment or prophylaxis of Pneumocystis carinii pneumonia. J Protozool 1989; 36: 77S – 78S. CrossRef | PubMed | CAS | Web of Science® Times Cited: 1; 5 Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Atovaquone has been investigated as an alternative agent for oral use in the treatment of both mild to moderate Pneumocystis carinii pneumonia (PCP) and toxoplasmosis, opportunistic infections commonly experienced by patients with AIDS.
11. Young RC, and DeVita JT: Treatment of Pneumocystis carinii pneumonia. Current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine, in Symposium on Pneumocystis carinii infection, National Cancer Institute Monograph 43, 1976, pp 193-198. 12.
Immunization with whole Pneumocystis carinii has been shown to protect mice from the development of P. carinii pneumonia (PCP) when they are subsequently immunosuppressed and challenged with viable organisms. To determine whether these results could be duplicated by using a subunit vaccine, we examined the immunogenicity and efficacy of an immunization strategy based on P. carinii gpA.